Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubamatamab Plus Chemotherapy and Bevacizumab in Ovarian Cancer
NCT07637851Phase 2Not yet recruiting
- Sponsor
- ARCAGY
- Start
- Aug 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ubamatamab in ovarian cancer, sponsored by ARCAGY. Primary endpoints: Dose-Limiting Toxicities at 4 weeks, Safety and Tolerability and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ubamatamab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07637851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07637851.